← Back to Home

Delivering DNA into the Cell Nucleus: Seawolf Raises $100 Million and Partners with Sanofi to Develop New Therapies

Seawolf aims to enable cells to keep producing therapeutic proteins while retaining the flexibility to administer additional doses. Its nonviral DNA delivery technology has attracted funding and a pharmaceutical partnership, but whether it can deliver both durability and safety in humans remains to be established in clinical trials.

By SURL BioNews

Enabling cells to produce therapeutic proteins themselves requires more than delivering genetic instructions. It also depends on how long those instructions last and whether they can be replenished when needed. Seawolf Therapeutics is tackling these challenges with nonviral DNA delivery technology. The U.S. biotechnology company announced on November 16 that it had secured $100 million in financing and signed a collaboration agreement with Sanofi to advance its platform, which remains at the preclinical stage, into the next phase of development.

The $100 million includes a seed round led by Versant Ventures and a subsequent Series A financing, with participation from investors including MPM BioImpact and Novartis Venture Fund. Another development avenue comes through Sanofi: the companies will undertake a multitarget research collaboration and exclusive licensing arrangement focused on bleeding disorders and other undisclosed indications. Seawolf could receive up to $1.2 billion in research, development and commercial milestone payments, plus tiered sales royalties. That ceiling does not represent money already received, and the announcement did not disclose an upfront payment.

At the heart of the collaboration is the TRIDENT platform. According to the company, the system combines proprietary lipid nanoparticles, DNA carrying therapeutic genes, and helper factors that assist DNA in entering the cell nucleus. The barrier it seeks to overcome is delivering DNA to the location within the cell where these instructions can be read, enabling the cell to produce the required protein.

Seawolf's design aims to extend the duration of protein expression while retaining the possibility of repeat dosing. If both properties hold true in humans, doses could potentially be replenished or adjusted according to treatment needs. However, sustained expression and repeat dosing remain capabilities that the platform must demonstrate clinically. Neither efficacy nor immune safety can be inferred solely from the delivery method.

The company says it has established proof of concept in primates and mouse models of metabolic and rare diseases, and claims that primate studies showed sustained therapeutic protein expression and good tolerability. However, the public announcement did not provide animal numbers, full dosing information, follow-up duration or detailed safety data. What readers can currently assess is therefore largely the company's description of its preclinical results.

For its internal pipeline, Seawolf will prioritize a metabolic disease program. BioSpace reported that the company has not disclosed further details of its first asset, leaving the specific disease, therapeutic target and drug candidate unclear. According to Reuters, the company aims to submit its first application for a human trial by the end of 2028. This is a development timeline target and does not mean that the trial has been approved or is certain to begin by then.

The financing and Sanofi collaboration provide resources to advance the technology and add another development path for nonviral DNA medicines. What ultimately determines its value will be data that can be examined: how long protein expression lasts, whether repeat dosing remains effective, and whether long-term exposure introduces new safety issues. Those answers will gradually turn the platform concept into therapies available to patients.

References

  1. Reuters via Euronext
  2. Seawolf Therapeutics via Business Wire / BioSpace
  3. BioSpace